Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Understanding and controlling the spread of antimalarial resistance, particularly to
artemisinin and its partner drugs, is a top priority. Plasmodium falciparum parasites resistant …

Highlights•Mutant K13-mediated artemisinin resistance involves reduced hemoglobin
endocytosis.•Artemisinin partial resistance has emerged in Africa.•Novel PfCRT mutations …

Various boron-containing drugs have been approved for clinical use over the past two
decades, and more are currently in clinical trials. The increasing interest in boron-containing …

Malaria has been a global epidemic health threat since ancient times. It still claims roughly
half a million lives every year in this century. Artemisinin and its derivatives, are frontline …

Intensified treatment and control efforts since the early 2000s have dramatically reduced the
burden of Plasmodium falciparum malaria. However, drug resistance threatens to derail this …

Mature red blood cells (RBCs) lack internal organelles and canonical defense mechanisms,
making them both a fascinating host cell, in general, and an intriguing choice for the deadly …

The Malaria Drug Accelerator (MalDA) is a consortium of 15 leading scientific laboratories.
The aim of MalDA is to improve and accelerate the early antimalarial drug discovery process …

Identifying how small molecules act to kill malaria parasites can lead to new “chemically
validated” targets. By pressuring Plasmodium falciparum asexual blood stage parasites with …

We report detailed susceptibility profiling of asexual blood stages of the malaria parasite
Plasmodium falciparum to clinical and experimental antimalarials, combined with …